throbber
European Journal of Pharmaceutical Sciences 97 (2017) 237–246
`
`Contents lists available at ScienceDirect
`
`European Journal of Pharmaceutical Sciences
`
`j o u r n a l h o m e pa ge : ww w . e l s e v i e r . c o m / l oc a t e / e j p s
`
`The formation and physical stability of two-phase solid dispersion
`systems of indomethacin in supercooled molten mixtures with different
`matrix formers
`Kristian Semjonov a,⁎, Karin Kogermann a, Ivo Laidmäe a, Osmo Antikainen b, Clare J Strachan b, Henrik Ehlers b,
`Jouko Yliruusi b, Jyrki Heinämäki a
`a Institute of Pharmacy, Faculty of Medicine, University of Tartu, Nooruse 1, 50411 Tartu, Estonia
`b Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, Viikinkaari 5E, 00014, University of Helsinki, Finland
`
`a r t i c l e
`
`i n f o
`
`a b s t r a c t
`
`Article history:
`Received 29 February 2016
`Received in revised form 10 November 2016
`Accepted 16 November 2016
`Available online 24 November 2016
`
`Keywords:
`Solid dispersion
`Two-phase systems
`Supercooled molten mixture
`Indomethacin
`Soluplus®
`Xylitol
`Solid-state stability
`
`Amorphous solid dispersions (SDs) are a promising approach to improve the dissolution rate of and oral bioavail-
`ability of poorly water-soluble drugs. In some cases multi-phase, instead of single-phase, SD systems with
`amorphous drug are obtained. While it is widely assumed that one-phase amorphous systems are desirable,
`two-phase systems may still potentially exhibit enhanced stability and dissolution advantages over undispersed
`systems. The objective of the present study was to understand the solid-state properties of two-phase SDs with
`amorphous drug and their relation to physical stability. Two different types of excipients for SD formation were
`used, one being a polymer and the other a small molecule excipient. The supercooled molten SDs of a poorly
`water-soluble indomethacin (IND) with a graft copolymer, Soluplus® (SOL) and sugar alcohol, xylitol (XYL)
`were prepared. Supercooled molten SDs of IND with SOL were two-phase glassy suspension in which the amor-
`phous drug was dispersed in an amorphous polymer matrix. A short-term aging of the SDs led to the formation
`of glassy suspensions where the crystalline drug was dispersed in an amorphous polymer matrix. These were
`physically stable at room temperature for the time period studied (RT, 23 ± 2 °C), but aging at high-humidity
`conditions (75% RH) recrystallization to metastable α-IND occurred. Interestingly, the SDs with XYL were two-
`phase amorphous precipitation systems in which the drug was in an amorphous form in the crystalline sugar alco-
`hol matrix. The SDs of IND and XYL exhibited fast drug recrystallization. In conclusion, the preparation method of
`two-phase systems via co-melting in association with the rapid quench cooling is a feasible method for the for-
`mulation of poorly water-soluble drugs. The physical stability of these two-phase systems, however, is depen-
`dent on the carrier material and storage conditions.
`
`© 2016 Elsevier B.V. All rights reserved.
`
`1. Introduction
`
`The adoption of new formulation strategies for poorly water-soluble
`drugs are currently of great interest, since the majority of the new drug
`candidates emerging from the drug development pipeline are poorly
`water-soluble compounds (Brough and Williams III, 2013). The com-
`monly used formulation approaches for poorly water-soluble drugs in-
`clude solid dispersions (SDs), and to date the advantages of SDs over
`other strategies are well-documented (Vasconcelos et al., 2007). During
`the past two decades, the fabrication of SDs has been substantially de-
`veloped due to the availability of new types of carriers (vehicles) and
`
`⁎ Corresponding author.
`E-mail addresses: kristian.semjonov@ut.ee (K. Semjonov), karin.kogerman@ut.ee
`(K. Kogermann), ivo.laidmae@ut.ee (I. Laidmäe), osmo.antikainen@helsinki.fi
`(O. Antikainen), clare.strachan@helsinki.fi (C.J. Strachan), henrik.ehlers@helsinki.fi
`(H. Ehlers), jouko.yliruusi@helsinki.fi (J. Yliruusi), jyrki.heinamaki@ut.ee (J. Heinämäki).
`
`new manufacturing technologies (Serajuddin, 1999; Vasconcelos et al.,
`2007; Janssens and Van den Moorter, 2009).
`The SDs for pharmaceutical applications are commonly fabricated by
`melting (fusion), melting solvent, solvent evaporation, extrusion, spray-
`drying or supercritical fluid method. In SDs, the drug is dispersed within
`a carrier (vehicle) matrix (either polymeric or small molecular matrix).
`Different types of SDs can be classified into one-phase or two-phase sys-
`tems (Janssens and Van den Mooter, 2009). In one-phase systems, the
`drug is molecularly dispersed within the carrier and both components
`exist in the amorphous phase (or as a co-crystal if crystalline). Such for-
`mulations are widely considered as the most desired form, however
`one-phase systems limit drug loading, may not always be achievable,
`and the dissolution may be even worse if the intermolecular binding be-
`tween the drug and matrix material is too strong. Poor dissolution has,
`for example, been observed with one-phase indomethacin and
`Soluplus® solid dispersions (Surwase et al., 2015). With these factors
`in mind, one can also consider two-phase systems. In two-phase
`
`http://dx.doi.org/10.1016/j.ejps.2016.11.019
`0928-0987/© 2016 Elsevier B.V. All rights reserved.
`
`Purdue 2023
`Collegium v. Purdue, PGR2018-00048
`
`

`

`238
`
`K. Semjonov et al. / European Journal of Pharmaceutical Sciences 97 (2017) 237–246
`
`systems, the components can be present as independent crystalline
`and/or crystalline/amorphous phase. Thommes et al. (2011) prepared
`crystalline suspension by hot melt extrusion (HME), where crystalline
`drug was molecularly dispersed in crystalline sugar. The formulation
`can act as physical mixture, nevertheless with significant enhancing
`effect on dissolution properties. (Thommes et al., 2011; Thommes,
`2012;)
`The fabrication of SDs by the melting (or fusion) involves heating the
`drug and carrier above their melting or glass transition temperatures,
`followed by mixing and cooling (Janssens and Van den Moorter,
`2009). The properties of SDs can vary greatly depending on the method
`of preparation, process conditions (heating rate, melting temperature,
`cooling method and rate, grinding, etc.), and materials selection (phys-
`icochemical properties of the drug and carrier, drug-carrier interac-
`tions) (Serajuddin, 1999; Thommes et al., 2011). For obtaining the
`one-phase molecularly dispersed system, the complete miscibility of
`the drug and the carrier in the molten form is crucial (Leuner and
`Dressman, 2000). Recently, Thommes et al. (2011) prepared by a hot-
`melt extrusion method a two-phase SD (crystalline suspension), in
`which crystalline drug was dispersed in crystalline sugar. The present
`SDs significantly enhanced the dissolution properties of a poorly
`water-soluble drug (Thommes et al., 2011; Thommes, 2012).
`Since SDs are typically thermodynamically unstable systems, there is
`an increased risk for the spontaneous recrystallization of the drug to
`crystalline polymorph, and consequently, the loss of its favourable per-
`formance (Vasconcelos et al., 2007; Williams et al., 2013). Several stabi-
`lization mechanisms of amorphous drug in the molecular dispersion
`have been described including (1) reduced molecular mobility due to
`increased local viscosity (Aso et al., 2004; Van Den Mooter, 2012), (2)
`intermolecular interaction between the drug and carrier polymer
`(Sethia and Squillante, 2004) and (3) prevention of nuclei formation
`and crystal growth (Marsac et al., 2009). Nevertheless, most pharma-
`ceutical SDs are only partially miscible systems and thus are supersatu-
`rated with respect to the drug in the polymer, and phase separation is
`dependent on the physicochemical properties of the drug, the drug
`weight fraction and the carrier used in the SD (Janssens and Van den
`Moorter, 2009). In summary, the SDs can exist as one-phase or two-
`phase systems, and the physical state/stability of SDs are dependent
`on both materials and the method of preparation (process and technol-
`ogy). Molecular level interactions, steric hindrance and reduced inter-
`face molecular mobility (compared to an air-water interface) all play a
`significant role in the physical stabilisation of SDs (Janssens and Van
`den Moorter, 2009).
`Indomethacin (IND) is a widely-used non-steroidal anti-inflam-
`matory drug, and is a commonly used model drug in the develop-
`ment of amorphous systems for poorly water-soluble drugs (Hart
`and Boardman, 1963; Ewing et al., 2014; Dimensional et al., 2015).
`IND has two crystalline polymorphs (α and γ forms), and an amor-
`phous form (Savolainen et al., 2007; Strachan et al., 2007; Atef et
`al., 2012). Recently, Surwase et al. (2013) discovered and character-
`
`ized several new polymorphs (ɛ, ζ, η) for IND, which were prepared
`
`under different crystallization conditions (Surwase et al., 2013).
`Soluplus® (SOL) is a new amorphous block copolymer consisting of
`hydrophilic repeating units of polyethylene glycol 6000 and hydro-
`phobic segments of polyvinyl acetate and polyvinyl caprolactam.
`Originally, SOL was designed for preparing the solid solutions of
`poorly water-soluble drugs by hot-melt extrusion technology (Basf,
`The Chemical Company, Soluplus, Technical Information, 2010). SOL
`has been studied as a stabilizer of amorphous systems, providing hy-
`drogen bond donors (\\OH) and acceptors (C_O) (Zhang et al.,
`2012; Kogermann et al., 2013; Paaver et al., 2014; Lust et al., 2015).
`Xylitol (XYL) is sugar alcohol, which has gained interest in the uses
`as a small-molecular matrix of SDs for improving the solubility of
`poorly water-soluble drugs (Mummaneni and Vasavada, 1990;
`Sjökvist and Nyström, 1991; Singh et al., 2011). The chemical struc-
`ture of IND, SOL and XYL is shown in Fig. 1.
`
`Fig. 1. Molecular structures of pure materials: a) indomethacin (IND); b) Soluplus® (SOL);
`Xylitol (XYL).
`
`The aim of the present study was to investigate the formation and
`physical state/solid-state stability of SDs of a poorly water-soluble
`drug (IND) in two-phase supercooled molten mixtures with a graft co-
`polymer, Soluplus® (SOL) and a sugar alcohol (XYL). Special attention
`was paid on (1) the physical state of the SDs (i.e., the supercooled mol-
`ten mixtures with either a polymer or small molecular matrix former);
`(2) the solid-state stabilisation mechanisms of the SDs where the drug
`is dispersed within a polymeric or small molecular matrix; and (3) the
`significance of matrix former in the stability of such systems (the hy-
`pothesis is that the present matrix formers can attribute as solid-state
`stabilizers of IND in the present SDs).
`
`2. Materials and methods
`
`2.1. Materials
`
`Indomethacin, IND (1-(p-chlorobenzoyl)-5-methoxy-2-methylin
`dole-3-acetic acid) was purchased from Hawkins (USA) as the γ poly-
`morphic form (γ-IND). The α-IND was obtained by dissolving the
`γ-IND in ethanol at 80 °C and precipitating with Milli-Q-water at
`room temperature (RT, 23 ± 2 °C). The precipitated mass was vac-
`uum filtered and dried overnight (Savolainen et al., 2007). The
`amorphous form of IND was prepared by melting the γ-IND on a
`stainless steel dish at approximately 175 °C and quench cooled
`(QC) by pouring liquid nitrogen on to it. Soluplus® (SOL) graft co-
`polymer and xylitol (XYL) were obtained from BASF (Germany)
`and Yliopiston Apteekki (Helsinki), respectively. All molecular
`structures of pure materials are presented on Fig. 1.
`
`2.2. Methods
`
`2.2.1. Preparation of solid dispersions (SD) and corresponding physical
`mixtures (PM)
`Supercooled co-melted solid dispersion (SD) mixtures were pre-
`pared by melting the γ-IND in a stainless steel dish at approximately
`175 °C and then adding SOL/XYL. The molten mass was solidified by
`pouring liquid nitrogen onto the stainless steel dish. The molten mass
`was then gently ground in a mortar. Corresponding physical mixtures
`(PMs) of drug and carrier with a batch size of 5 g were prepared by
`mixing the components with a pestle in a mortar and using geometric
`dilution. PMs were prepared with SOL/XYL and both IND polymorphs
`(γ-IND and α-IND). All samples (supercooled co-melted SD mixtures
`and PMs) were sieved using a mesh of 450 μm and the fraction passing
`through was used. The drug:carrier weight ratios used in the
`supercooled co-molten SDs and corresponding PMs were 1:3, 1:6 and
`1:9 (w/w). The SDs and PMs with a drug-carrier weight ratio 3:1 and
`1:1 (w/w) were also prepared, but since these SDs showed a poor phys-
`ical stability (early-stage recrystallization within 48 days), these formu-
`lations were not further tested.
`
`Purdue 2023
`Collegium v. Purdue, PGR2018-00048
`
`

`

`K. Semjonov et al. / European Journal of Pharmaceutical Sciences 97 (2017) 237–246
`
`239
`
`2.2.2. Storage conditions and physical stability measurements
`For assessing the physical stability of prepared multi-phase SD sys-
`tems (possible phase transitions and/or polymorphic changes), the
`supercooled molten SDs were stored in open glass petri dishes at 0%
`RH, 50% RH and 75% RH at RT (23 ± 2 °C) for up to 2 months. The sam-
`ples of the aged SDs stored under 50% and 75% RH were taken periodi-
`cally every 24 h during the first week, and subsequently after 10 days,
`14 days, 21 days and 27 days. The samples stored at 0% RH were moni-
`tored for up to 2 months. In addition, the SD of IND with XYL (a drug-
`carrier ratio 1:3) was taken for the short accelerated stability testing
`and stored only at 50% RH/RT up to 4 days.
`
`2.2.3. Scanning electron microscopy (SEM)
`The physical appearance of pure materials, SDs and PMs were inves-
`tigated with a high resolution SEM (FEI Quanta™ 250, Netherlands). The
`samples were sputter coated with a thin platinum layer in nitrogen at-
`mosphere on a carbon tape and examined with a large field low vacuum
`secondary electron detector (LFD) at different magnifications. The SEM
`images were analyzed using ImageJ software (version 1.50b). Martin's
`diameter was used for calculating the average particle size and present-
`ed as the mean ± standard deviation (SD) (n = 60).
`
`2.2.4. Solid state characterisation
`
`variable-temperature XRPD (VT-XRPD) experiments were conducted
`with pure materials (γ-IND, amorphous IND, XYL, QC XYL) and the
`supercooled molten SDs in 1:3 weight ratio (IND:SOL and IND:XYL).
`XRPD (VT-XRPD) was used for tracking the heat induced solid-state
`transitions and understanding the miscibility of the systems and
`revealing the presence of multi-phase system. Data were collected
`from 8 to 22.5° 2θ, with a step size of 0.0195° 2θ. The heating process
`started from RT at a rate of 0.5 °C/min and the first scan was taken at
`30 °C and other scans were measured at intervals of 10 °C up to
`150 °C for IND:SOL systems and after every 5 °C until 160 °C for all sys-
`tems. The heated samples were then cooled down to 30 °C and
`remeasured. The total scan time at each investigated temperature was
`ca 16 min. Amorphous IND and XYL were prepared prior inserting the
`sample to the VT-XRPD.
`
`2.2.4.2. Fourier transform infrared spectroscopy (FT-IR). A FT-IR spectrom-
`eter (Vertex 70, DTGS detector, Bruker, Germany) with a MIRacle™
`(PIKE Technologies, Inc., US) single reflection attenuated total reflection
`(ATR) crystal was used for collecting the spectra. The spectral region
`from 650 to 4000 cm−1 was collected as an accumulation of 64 scans.
`A total of 3 spectra were taken from each sample and presented as an
`average. The spectra were analyzed and processed in OriginPro software
`(version 9.1).
`
`2.2.4.1. X-ray powder diffraction (XRPD). The samples were studied with
`XRPD using the Bruker D8 Advanced diffractometer (Bruker AXS GmbH,
`Germany) with Cu K-alpha1 radiation λ = 1.5406 Å, operated at 40 kV
`and 40 mA. A Vario1 focusing primary monochromator, two 2.5° Soller
`slits and LynxEye line detector were used. Data were collected in θ–2θ
`geometry in the range of 5–30° 2θ, with the step size of 0.0195° 2θ
`from 5 to 30° 2θ and a total counting time of 49.8 s per step. The
`
`2.2.5. Thermal analysis
`Differential scanning calorimetry (DSC) thermograms were obtain-
`ed with a DSC823e (Mettler Toledo AG, Switzerland) and analyzed
`using STARe software (version 9.0). Samples with the weight of 6–
`7 mg were encapsulated into aluminium pans with two holes in the
`lid and heated with the isothermal step at 30 °C for 5 min up to
`200 °C. The heating rate of 20 °C/min in the inert nitrogen atmosphere
`
`Fig. 2. Scanning electron microscopy (SEM) micrographs of the solid dispersions (SDs) and respective physical mixtures (PMs) of γ-indomethacin (IND) with carrier materials. Key: A. The
`1:3 SD of IND with Soluplus® (SOL) (drug:polymer); B. The 1:3 PM of γ-IND with SOL (drug:polymer); C. The 1:3 SD of IND with xylitol (XYL) (drug:sugar alcohol); D. The 1:3 PM of γ-IND
`with XYL (drug:sugar alcohol). Magnification of SEMs ×100. Numbers in the up right corner indicate the average particle size ± SD.
`
`Purdue 2023
`Collegium v. Purdue, PGR2018-00048
`
`

`

`240
`
`K. Semjonov et al. / European Journal of Pharmaceutical Sciences 97 (2017) 237–246
`
`with a flow rate of 50 ml/min was used. Indium was used for the valida-
`tion of the DSC system. Modulated temperature DSC (MT-DSC) was
`used to determine the glass transition temperature (Tg) of SDs from 0
`to 180 °C/min at the heating rate of 2 °C/min and pulse height of
`0.5 °C and 30 s pulse width. Conventional DSC was not sensitive enough
`to separate overlapping events at Tg region.
`Hot-stage microscopy (HSM) was performed with a Mettler Toledo
`F82 (Switzerland) and visualized with a polarized light microscope
`(Leica DM/LM, Germany) under 5× magnification (HSM-PLM). The
`video and images were captured using full HD-video and 13.0 mega-
`pixel equipped camera with full auto focus function. The temperature
`range and heating rate were chosen as in the DSC experiments from
`30–200 °C and 20 °C/min. All temperatures are given as onset tempera-
`tures unless mentioned otherwise. The sample was run twice for pure
`materials and physical mixtures, once for SDs.
`
`2.2.6. Data analysis
`ImageJ (version 1.50b) software was used to measure the particle
`size (Martin's diameter) and particle size variation. ChemBioDraw
`Ultra (version 13.0) drawing program was used for structure generation.
`
`3. Results and discussion
`
`3.1. Particle size, shape and surface morphology
`
`Comparison of the SEM results of pure materials with those obtained
`with the supercooled molten SDs can help to indicate the influence of
`the method of preparation and carrier on the particle size, shape and
`
`surface morphology. All mixtures (1:3, 1:6, 1:9) were initially prepared,
`but only 1:3 was tested further. It was confirmed that the γ-IND exhib-
`ited flat, rectangular and sharp edged tiny crystals with the average SEM
`particle size of 51 ± 20 μm. Both stabilizing carrier materials, SOL graft
`copolymer and XYL, presented oblong shape, smooth surfaced particles
`with much larger average particle size (285 ± 68 μm for SOL and 235 ±
`89 μm for XYL) (Appendix 1). The average particle size of IND
`supercooled molten mixtures with SOL and XYL as well as the corre-
`sponding PMs was approximately 70 μm (Fig. 2). The SEM micrographs
`of the 1:3 SDs suggest that the γ-IND particles partially melted inside or
`were attached on the surface of SOL graft copolymer (Fig. 2A). The cor-
`responding micrographs of SDs containing IND and XYL at the weight
`ratio of 1:3 showed similar results, thus indicating that the drug parti-
`cles were dispersed in a XYL matrix (Fig. 2C).
`
`3.2. Physical solid-state properties
`
`The XRPD patterns of pure materials (γ-IND, α-IND, SOL and XYL),
`SDs and PMs are shown in Fig. 3. Characteristic XRPD reflections of all
`materials are summarized in Table 1. These results are in good accor-
`dance with the literature (Crowley and Zografi, 2003; Masuda et al.,
`2006; Bogdanova et al., 2007; Ueda et al., 2014). As seen in Fig. 3, pure
`SOL was XRPD amorphous with a broad halo across the entire pattern,
`XYL exhibited strong crystalline reflections.
`The XRPD patterns of the freshly prepared supercooled molten
`amorphous SDs and their corresponding PMs with γ-IND and SOL are
`shown in Fig. 3A–B. The absence of characteristic crystalline reflections
`of γ-IND in the supercooled molten SDs of IND with SOL at all
`
`Fig. 3. X-ray powder diffraction (XRPD) patterns of γ and α-indomethacin (IND), and the solid dispersions (SDs) and physical mixtures (PMs) of γ-IND with carrier materials. A. SDs with
`Soluplus® (SOL) IND:SOL in different weight ratios (1:3, 1:6, 1:9 (drug:polymer)), and B. its respective PMs; C. SDs with Xylitol (XYL) IND:XYL in different weight ratios (1:3, 1:6, 1:9
`(drug:polymer), and D. its respective PMs. In addition, pure material XRPD patterns (γ-IND, α-IND, SOL, XYL) are shown as references. All patterns are normalized. The (*) and (#)
`marks denote the reflections unique to γ-IND and α-IND, respectively.
`
`Purdue 2023
`Collegium v. Purdue, PGR2018-00048
`
`

`

`K. Semjonov et al. / European Journal of Pharmaceutical Sciences 97 (2017) 237–246
`
`241
`
`Table 1
`Summary of the physical storage stability of the supercooled molten SDs stored at 0% RH / RT; 50% RH / RT and 75% RH / RT for 1–8 weeks. The results are based on the XRPD, ATR-FTIR and
`DSC analyses (more detailed data are given in Appendix 3).
`
`Crystalline IND/storage conditions
`
`XRPD/
`
`DSC/°C
`
`ATR- FT-IR/cm−1
`
`Pure materials
`γ-IND
`α-IND
`
`11.7°, 19.6°, 21.8°, 26.6°
`8.4°, 14.4°, 18.5°, 22.0°
`
`Pure amorphous IND
`
`No reflections
`
`159.8 ± 0.4 (Tm)
`153.5 ± 0.5 (Tm)
`
`44.8 ± 0.8 (Tg)
`131.7 ± 0.5 (Tc)
`157.5 ± 0.1 (Tm)
`
`1714 cm−1, 1689 cm−1
`1734 cm−1, 1689 cm−1,
`1679 cm−1, 1649 cm−1
`1707 cm−1, 1680 cm−1
`
`Stored samples
`0%RH/RT
`IND:SOL 1:3
`
`50%RH/RT
`IND:SOL 1:3
`
`IND:XYL 1:3
`
`75%RH/RT
`IND:SOL 1:3
`
`NA- non-applicable
`
`First IND reflections detected after 1 week
`21.9°
`(γ-IND/α-IND)
`
`Tm detected after 2 months
`
`Changes in spectra detected after 2 months
`1680 cm−1 N 1686 cm−1
`
`152.5 ± 0.9
`(α-IND)
`
`NA
`
`First IND reflections detected after 1 week
`
`Tm detected after 1 week
`
`21.9°
`(γ-IND/α-IND)
`XYL reflections
`14°, 14.6°,17,6°,19,8°
`First IND reflections
`Detected after 4 days
`11.7°
`(γ-IND)
`
`155.9 ± 0.4
`(α-IND)
`Tm of XYL
`89.0 ± 1.4
`Tm of IND
`152.2 ± 0.1
`
`(α-IND)
`
`Changes in spectra detected after 2 weeks
`1682 cm−1N1688 cm−1
`NA
`
`NA
`
`First IND reflections detected after 1 week
`
`21.9°
`
`(γ-IND/α-IND)
`
`Tm detected after 1 week
`155.9 ± 0.4
`
`(α-IND)
`
`Changes in spectra detected after 2 and 10 days
`
`1632 cm−1N1612N1618
`1683 cm−1N1685N1691
`1732 cm−1N1722N1718
`NA
`
`drug:polymer weight ratios (1:3, 1:6, 1:9) indicated the formation of
`amorphous IND (Fig. 3A). The XRPD patterns of PMs of γ-IND and SOL
`showed characteristic crystalline reflections of γ-IND (Fig. 3B). As ex-
`pected, due to a dilution effect, the intensity of the reflections decreased
`as the amount of SOL in the PMs was increased. However, in spite of the
`reduced intensity the characteristic reflection of γ-IND at 11.7° 2θ was
`still observed at all weight ratios.
`The XRPD patterns for the supercooled molten SDs and their corre-
`sponding PMs with γ-IND and XYL are shown in Fig. 3C–D. Interestingly,
`the XRPD patterns at all tested drug:polymer weight ratios (1:3, 1:6,
`1:9) showed only crystalline XYL reflections with some amorphous
`halo. It is evident that the SDs containing IND and XYL formed two
`separate phases: an amorphous phase composed largely of IND and a
`crystalline phase composed of XYL (Fig. 3C). While the molecular size
`and arrangement of these molecules in XYL would likely preclude an
`(significant) incorporation of IND molecules into the crystalline phase
`(i.e. eutectics), one cannot exclude the presence of a certain amount
`XYL molecularly dispersed within the amorphous phase of the matrix,
`which is presumably IND rich. In the corresponding PMs, the character-
`istic reflections for both γ-IND and XYL were detected in all weight
`ratios.
`
`3.3. Thermal behaviour
`
`Understanding of the thermal phase behaviour and polymer-drug
`interactions of the two-phase binary system is of key importance for
`the selection of the most suitable carrier. Thermal stability of the fresh
`supercooled molten SDs at the weight ratio of 1:3 (drug:polymer) as
`well as drug-polymer miscibility was further studied using DSC, MT-
`DSC, HSM and VT-XRPD. As a reference, the thermal behaviour of all
`pure materials and corresponding PMs was studied. All thermal param-
`eters for different samples are depicted in Table 1, and the thermal
`
`behaviour of pure materials was in agreement with the literature
`(BASF, 2012; Bogdanova et al., 2007; Singh et al., 2011).
`
`3.3.1. Indomethacin-soluplus® (IND-SOL) solid dispersion (SD)
`In line with the XRPD results, the absence of a melting endotherm on
`the DSC thermograms of freshly prepared supercooled SDs with
`
`Fig. 4. Modulated-temperature differential scanning calorimetry (MT-DSC) thermograms
`of the fresh solid dispersions (SDs) of indomethacin (IND). Key: (A) SDs with Xylitol (XYL)
`IND:XYL in weight ratio of 1:3 (drug:polymer), (B) SDs with Soluplus® (SOL) IND:SOL in
`weight ratio of 1:3 (drug:polymer).
`
`Purdue 2023
`Collegium v. Purdue, PGR2018-00048
`
`

`

`242
`
`K. Semjonov et al. / European Journal of Pharmaceutical Sciences 97 (2017) 237–246
`
`IND:SOL confirmed the presence of XRPD amorphous systems (Table 1).
`Upon heating no heat-induced recrystallization was observed in the
`DSC thermograms. Due to the broad endothermic artifact from 30–
`100 °C in the conventional DSC, the Tg-s of amorphous IND and SOL
`were indistinguishable and it was impossible to understand the pres-
`ence or absence of multiple phases of this drug-carrier system. In
`order to investigate this further and unambiguously identify the Tg-s
`as well as classify the SDs according to their structure (one or multi-
`phase systems), MT-DSC experiments were conducted. Hence the MT-
`DSC with supercooled SDs of IND:SOL (1:3) system showed a two-
`phase SDs system, where on a reversing thermogram two Tg-s were
`clearly observed, one at 40.3 °C for amorphous IND and a second at
`approximately 88 °C for SOL (Fig. 4). Clear shift in Tg-s of IND-SOL SDs
`compared to pure materials confirmed some level of drug-polymer
`miscibility important for the stability of amorphous systems (Table 1).
`HSM-PLM was also used to visualize the DSC/MT-DSC results and get
`more insight into the phenomena occurring at the interfaces within SD
`and PM mixtures (Fig. 5). The supercooled molten IND:SOL mixtures
`were heterogeneous and consisted of darker particles and more yellow-
`ish particles, hence no birefringence was observed confirming the pres-
`ence of two-phase amorphous SDs system (Fig. 6A). Upon heating no
`crystals were observed in these systems, only the drug dissolution into
`a polymer melt was detected. Similar phenomenon has been described
`by Fini et al. (2008) with ibuprofen and diclofenac, when they
`
`investigated the interactions between these two drugs with different
`types of polyvinylpyrrolidones (PVP) in PMs and SDs (Fini et al., 2008).
`Interestingly, according to the VT-XRPD results, amorphous SDs of
`IND and SOL started to recrystallize as α-IND at 70 °C, which was also
`noticed for amorphous IND alone (Fig. 5A vs). The most pronounced re-
`flections of α-IND were detected at 100 °C (denoted with # on Fig. 5B).
`This confirmed that SOL is not able to entirely prevent the heat-induced
`phase separation and recrystallization of α-IND. Differences between
`VT-XRPD and other thermal techniques (DSC, MT-DSC, HSM-PLM) can
`be explained with much longer measurement time in the VT-XRPD ex-
`periments, which may induce more pronounced changes in the sample
`upon heating. (Mirza et al., 2006)
`
`3.3.2. Indomethacin-xylitol (IND-XYL) solid dispersion (SD)
`The DSC and MT-DSC thermograms of supercooled molten IND:XYL
`SDs showed two endothermic events (one for XYL at 89 °C and one for
`α-IND at 152 °C) and no change in Tg compared to pure materials, thus
`suggesting the presence of a poorly miscible two-phase drug-carrier
`system (Table 1). Since the recrystallization of IND was also detected
`at 124 °C, it is evident that XYL was not able to prevent the heat-induced
`solid-state changes of IND in these SDs. Furthermore, also VT-XRPD
`results using IND:XYL SDs (Figs. 5C and D) verified the DSC/MT-DSC
`results showing a two-phase system (Fig. 4).
`
`Fig. 5. Variable temperature X-ray powder diffraction patterns (VT-XRPD) (all patterns are normalized) of indomethacin (IND) fresh solid dispersions (SDs): A–B. SDs with Soluplus®
`(SOL) IND:SOL in weight ratio of 1:3 (drug:polymer) and C-D. SDs with Xylitol (XYL) IND:XYL in weight ratio of 1:3 (drug:polymer) in comparison to XRPD patterns of untreated
`crystalline IND forms, and pure stabilizer (SOL and/or XYL). Heating from 30 °C up to 160 °C. The (*) and (#) marks denote the reflections unique to γ-IND and α-IND, respectively.
`
`Purdue 2023
`Collegium v. Purdue, PGR2018-00048
`
`

`

`K. Semjonov et al. / European Journal of Pharmaceutical Sciences 97 (2017) 237–246
`
`243
`
`3.3.3. Physical mixtures (PMs) of IND:SOL and IND:XYL
`As expected the PMs of both systems (IND-SOL and IND-XYL)
`showed the characteristic thermal behaviour of two-phase systems
`(Table 1). The latter was also verified by HSM-PLM and VT-XRPD.
`HSM-PLM revealed that upon heating these two PMs systems showed
`clear distinguishable boundary of a drug containing phase (yellow)
`and transparent carrier phase (Fig. 6B and C). The corresponding
`drug-carrier incompatibility has been reported also with the SDs of ibu-
`profen and XYL (Greenhalgh et al., 1999).
`
`3.4. Drug-carrier interactions
`
`Since thermal analyses revealed that IND-SOL SD systems have some
`mixing between the components, the ATR-FTIR spectroscopy was used
`to examine further the possible molecular-level interactions between
`the drug and carrier in SD systems. The ATR FTIR spectra for pure mate-
`rials, the supercooled co-melted SDs systems of IND with SOL/XYL (in
`different drug-polymer ratios) and their corresponding PMs with γ-
`IND are shown in Fig. 7. The pure material spectra matched with the re-
`ported spectra in the literature (Bahl and Bogner, 2006; Strachan et al.,
`2007; Lan et al., 2010; Shamma and Basha, 2013).
`The ATR-FTIR spectra of IND-SOL amorphous SDs at all drug:polymer
`ratios showed strong absorption peaks at 1630 cm−1 and 1732 cm−1
`(Fig. 7A) which belong to SOL molecular vibrations (carbonyl groups
`of block sequences –polyvinylacetate O\\C_O\\CH and caprolactam
`C_O\\N vibrations, respectively). Since the pure amorphous IND also
`showed shoulder band at 1734 cm−1 and strong vibrations at
`1689 cm−1 and 1679 cm−1 (data not shown), the spectral overlap
`with strong SOL vibrations covered several amorphous IND peaks. How-
`ever, as evidenced by the MT-DSC results (shift in Tg of IND-SOL SDs
`compared to pure materials), some hydrogen-bond formation at the
`molecular level may have occurred between SOL and IND molecules
`during SD preparation (peak observed at 1680 cm−1). Zhang et al.
`(2013) described similar interaction with the SDs composed of
`itraconazole and SOL. The specific spectral regions of interest for the
`IND and XYL related interactions in SDs and PMs are at 1714 cm−1
`and 1689 cm−1 (both C_O of IND) and 3421 cm−1, 3359 cm−1, and
`3293 cm−1 (OH groups of XYL). As expected based on the thermal anal-
`ysis results, the FT-IR spectra showed limited compatibility between
`those two components since instead of the peak shift only intensity
`changes were detected in carbonyl and hydroxyl group vibrations. Sev-
`eral studies have shown limited ability of XYL to form chemical interac-
`tion with the active ingredients (Mummaneni and Vasavada, 1990;
`Sjökvist and Nyström, 1991; Suzuki and Sunada, 1997; Madgulkar et
`al., 2015).
`
`3.5. Physical stability during storage under different conditions
`
`According to the literature, molecularly dispersed single-phase SDs
`are the most stabilized systems against crystallization (Williams et al.,
`2013). Hence, the degree of miscibility between the drug and polymer
`is important for the formation of a physically stable amorphous system.
`Aging under different humidity conditions can change the physical
`solid-state properties and performance of two-phase SDs systems. In
`our study, the physical stability of the two-phase systems was investi-
`gated to understand their potential stabilizing mechanisms. Table 1
`summarizes the physical storage stability results (XRPD, DSC and ATR-
`FTIR) obtained with the aged supercooled molten amorphous SDs of
`IND:SOL and IND:XYL. Interestingly different analytical methods re-
`vealed somewhat different level of physical stability in these two-
`phase SD systems, thus giving further proof that complementary analy-
`sis methods are needed in order to obtain complete insight into the
`complex recrystallization behaviour.
`According to the XRPD, the supercooled molten SDs (with a IND:SOL
`weight ratio of 1:3) we

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket